Last 12 months
Inside the activity.
12 purchase rows · 6 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 10 | 0 |
| Mar 2026 | 2 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2018 Filed Jun 8, 2018 16:29 UTC |
SCHEDER-BIESCHIN MAXChief Financial Officer
|
Exercise / conversionCommon Stock | 9,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-036693 · doc4.xml · nonDerivative · entry 1 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Ekso Bionics Holdings, Inc. common stock. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 17:16 UTC |
Davault GregoryVice Pres., Global Marketing
|
Tax withholdingCommon Stock | 8,655 | $1.53 | $13,199.74 |
DisclosureSEC source: 0001209191-18-021773 · doc4.xml · nonDerivative · entry 2 Davault Gregory · CIK 0001694979 · Vice Pres., Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,235 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.50 to $1.54, inclusive. The reporting person undertakes to provide to Ekso Bionics Holdings, Inc., any security holder of Ekso Bionics Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 17:13 UTC |
DeLonzor RussVice Pres., Operations
|
Tax withholdingCommon Stock | 9,400 | $1.52 | $14,250.40 |
DisclosureSEC source: 0001209191-18-021771 · doc4.xml · nonDerivative · entry 2 DeLonzor Russ · CIK 0001694985 · Vice Pres., Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,969 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.50 to $1.54, inclusive. The reporting person undertakes to provide to Ekso Bionics Holdings, Inc., any security holder of Ekso Bionics Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 17:05 UTC |
SCHEDER-BIESCHIN MAXChief Financial Officer
|
Tax withholdingCommon Stock | 17,836 | $1.54 | $27,481.71 |
DisclosureSEC source: 0001209191-18-021763 · doc4.xml · nonDerivative · entry 2 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,860 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.53 to $1.56, inclusive. The reporting person undertakes to provide to Ekso Bionics Holdings, Inc., any security holder of Ekso Bionics Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 21:09 UTC |
Angold RussPresident, EksoWorks
|
Tax withholdingCommon Stock | 3,976 | $1.51 | $6,004.95 |
DisclosureSEC source: 0001209191-18-021768 · doc4.xml · nonDerivative · entry 2 Angold Russ · CIK 0001640210 · President, EksoWorks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,669 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.51 to $1.5146, inclusive. The reporting person undertakes to provide to Ekso Bionics Holdings, Inc., any security holder of Ekso Bionics Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| March 22, 2018 Filed Mar 27, 2018 17:16 UTC |
Davault GregoryVice Pres., Global Marketing
|
GrantCommon Stock | 22,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-021773 · doc4.xml · nonDerivative · entry 1 Davault Gregory · CIK 0001694979 · Vice Pres., Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,890 Read SEC document |
| March 22, 2018 Filed Mar 27, 2018 17:13 UTC |
DeLonzor RussVice Pres., Operations
|
GrantCommon Stock | 24,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-021771 · doc4.xml · nonDerivative · entry 1 DeLonzor Russ · CIK 0001694985 · Vice Pres., Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,369 Read SEC document |
| March 22, 2018 Filed Mar 27, 2018 17:05 UTC |
SCHEDER-BIESCHIN MAXChief Financial Officer
|
GrantCommon Stock | 57,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-021763 · doc4.xml · nonDerivative · entry 1 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,696 Read SEC document |
| March 22, 2018 Filed Mar 27, 2018 21:09 UTC |
Angold RussPresident, EksoWorks
|
GrantCommon Stock | 10,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-021768 · doc4.xml · nonDerivative · entry 1 Angold Russ · CIK 0001640210 · President, EksoWorks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,645 Read SEC document |
| November 22, 2017 Filed Nov 27, 2017 21:12 UTC |
Angold RussPresident, EksoWorks
|
SaleCommon Stock | 50,000 | $3.51 | $175,500.00 |
DisclosureSEC source: 0001455244-17-000052 · edgar.xml · nonDerivative · entry 1 Angold Russ · CIK 0001640210 · President, EksoWorks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,326 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.49 to $3.54, inclusive. The reporting person undertakes to provide to Ekso Bionics Holdings, Inc., any security holder of Ekso Bionics Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| September 14, 2017 Filed Sep 15, 2017 21:05 UTC |
Wendell Amy McBrideDirector
|
PurchaseCommon Stock | 16,264 | $1.23 | $20,004.72 |
DisclosureSEC source: 0001455244-17-000041 · edgar.xml · nonDerivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,264 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.22 to $1.24, inclusive. The reporting person undertakes to provide to Ekso Bionics Holdings, Inc., any security holder of Ekso Bionics Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| September 14, 2017 Filed Sep 18, 2017 22:47 UTC |
Peurach JackDirector
|
PurchaseCommon Stock | 20,000 | $1.27 | $25,400.00 |
DisclosureSEC source: 0001455244-17-000043 · edgar.xml · nonDerivative · entry 1 Peurach Jack · CIK 0001640206 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,224 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.265 to $1.27, inclusive. The reporting person undertakes to provide to Ekso Bionics Holdings, Inc., any security holder of Ekso Bionics Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| September 08, 2017 Filed Sep 12, 2017 22:47 UTC |
Looby ThomasDirector · President & CEO
|
PurchaseCommon Stock | 15,000 | $1.13 | $16,950.00 |
DisclosureSEC source: 0001455244-17-000039 · edgar.xml · nonDerivative · entry 1 Looby Thomas · CIK 0001640215 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,315 Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 13:26 UTC |
SCHEDER-BIESCHIN MAXChief Financial Officer
|
PurchaseCommon Stock | 10,000 | $1.13 | $11,300.00 |
DisclosureSEC source: 0001455244-17-000037 · edgar.xml · nonDerivative · entry 1 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,371 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.11 to $1.14, inclusive. The reporting person undertakes to provide to Ekso Bionics Holdings, Inc., any security holder of Ekso Bionics Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 18:21 UTC |
Davault GregoryVice Pres., Global Marketing
|
OtherSubscription Rights (right to buy) · Derivative | 1,429 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001455244-17-000034 · edgar.xml · derivative · entry 2 Davault Gregory · CIK 0001694979 · Vice Pres., Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,829 shares Expires 2017-08-31 Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 18:21 UTC |
Davault GregoryVice Pres., Global Marketing
|
OtherCommon Stock | 1,829 | $1.00 | $1,829.00 |
DisclosureSEC source: 0001455244-17-000034 · edgar.xml · nonDerivative · entry 1 Davault Gregory · CIK 0001694979 · Vice Pres., Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,258 F1 · shares: On August 14, 2017, Ekso Bionics Holdings, Inc. (the "Company") issued a press release announcing the commencement of a pro rata offering (the "Rights Offering") of rights to holders of the Company's common stock and certain holders of warrants issued by the Company, as of the record date of August 10, 2017, to subscribe for up to an aggregate of 34,000,000 shares of common stock. Each subscription right included a basic subscription right, which entitled its holder to purchase 1.1608 shares of common stock at a subscription price of $1.00, and an over-subscription right, which entitled its holder to purchase up to 1.1608 shares of common stock at a subscription price of $1.00, subject to the availability and pro rata allocation of shares among rights holders exercising their over-subscription rights. F2 · shares: The reporting person exercised in full his basic subscription rights, pursuant to which he acquired 1,658 shares of common stock. The reporting person also exercised 148 of his over-subscription rights for an additional 171 shares of common stock. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 18:19 UTC |
SCHEDER-BIESCHIN MAXChief Financial Officer
|
OtherSubscription Rights (right to buy) · Derivative | 9,817 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001455244-17-000033 · edgar.xml · derivative · entry 2 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,554 shares Expires 2017-08-31 Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 18:19 UTC |
SCHEDER-BIESCHIN MAXChief Financial Officer
|
OtherCommon Stock | 12,554 | $1.00 | $12,554.00 |
DisclosureSEC source: 0001455244-17-000033 · edgar.xml · nonDerivative · entry 1 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,371 F1 · shares: On August 14, 2017, Ekso Bionics Holdings, Inc. (the "Company") issued a press release announcing the commencement of a pro rata offering (the "Rights Offering") of rights to holders of the Company's common stock and certain holders of warrants issued by the Company, as of the record date of August 10, 2017, to subscribe for up to an aggregate of 34,000,000 shares of common stock. Each subscription right included a basic subscription right, which entitled its holder to purchase 1.1608 shares of common stock at a subscription price of $1.00, and an over-subscription right, which entitled its holder to purchase up to 1.1608 shares of common stock at a subscription price of $1.00, subject to the availability and pro rata allocation of shares among rights holders exercising their over-subscription rights. F2 · shares: The reporting person exercised in full his basic subscription rights, pursuant to which he acquired 11,394 shares of common stock. The reporting person also exercised 1,000 of his over-subscription rights for an additional 1,160 shares of common stock. Read SEC document |
| August 31, 2017 Filed Sep 6, 2017 01:05 UTC |
Looby ThomasDirector · President & CEO
|
OtherSubscription Rights (right to buy) · Derivative | 1,601 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001455244-17-000035 · edgar.xml · derivative · entry 2 Looby Thomas · CIK 0001640215 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,714 shares Expires 2017-08-31 Read SEC document |
| August 31, 2017 Filed Sep 6, 2017 01:05 UTC |
Looby ThomasDirector · President & CEO
|
OtherCommon Stock | 3,714 | $1.00 | $3,714.00 |
DisclosureSEC source: 0001455244-17-000035 · edgar.xml · nonDerivative · entry 1 Looby Thomas · CIK 0001640215 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,315 F1 · shares: On August 14, 2017, Ekso Bionics Holdings, Inc. (the "Company") issued a press release announcing the commencement of a pro rata offering (the "Rights Offering") of rights to holders of the Company's common stock and certain holders of warrants issued by the Company, as of the record date of August 10, 2017, to subscribe for up to an aggregate of 34,000,000 shares of common stock. Each subscription right included a basic subscription right, which entitled its holder to purchase 1.1608 shares of common stock at a subscription price of $1.00, and an over-subscription right, which entitled its holder to purchase up to 1.1608 shares of common stock at a subscription price of $1.00, subject to the availability and pro rata allocation of shares among rights holders exercising their over-subscription rights. F2 · shares: The reporting person exercised in full his basic subscription rights, pursuant to which he acquired 1,857 shares of common stock. The reporting person also exercised in full his over-subscription rights for an additional 1,857 shares of common stock. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 22:18 UTC |
Angold RussPresident, EksoWorks
|
OtherSubscription Rights (right to buy) · Derivative | 172,295 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001455244-17-000032 · edgar.xml · derivative · entry 2 Angold Russ · CIK 0001640210 · President, EksoWorks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2017-08-31 Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 22:18 UTC |
Angold RussPresident, EksoWorks
|
OtherCommon Stock | 200,000 | $1.00 | $200,000.00 |
DisclosureSEC source: 0001455244-17-000032 · edgar.xml · nonDerivative · entry 1 Angold Russ · CIK 0001640210 · President, EksoWorks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,326 F1 · shares: On August 14, 2017, Ekso Bionics Holdings, Inc. (the "Company") issued a press release announcing the commencement of a pro rata offering (the "Rights Offering") of rights to holders of the Company's common stock and certain holders of warrants issued by the Company, as of the record date of August 10, 2017, to subscribe for up to an aggregate of 34,000,000 shares of common stock. Each subscription right included a basic subscription right, which entitled its holder to purchase 1.1608 shares of common stock at a subscription price of $1.00, and an over-subscription right, which entitled its holder to purchase up to 1.1608 shares of common stock at a subscription price of $1.00, subject to the availability and pro rata allocation of shares among rights holders exercising their over-subscription rights. F2 · shares: The reporting person exercised 172,295 of his basic subscription rights, pursuant to which he acquired 200,000 shares of common stock. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 22:16 UTC |
Peurach JackDirector
|
OtherSubscription Rights (right to buy) · Derivative | 13,062 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001455244-17-000031 · edgar.xml · derivative · entry 2 Peurach Jack · CIK 0001640206 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,162 shares Expires 2017-08-31 Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 22:16 UTC |
Peurach JackDirector
|
OtherCommon Stock | 15,162 | $1.00 | $15,162.00 |
DisclosureSEC source: 0001455244-17-000031 · edgar.xml · nonDerivative · entry 1 Peurach Jack · CIK 0001640206 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,224 F1 · shares: On August 14, 2017, Ekso Bionics Holdings, Inc. (the "Company") issued a press release announcing the commencement of a pro rata offering (the "Rights Offering") of rights to holders of the Company's common stock and certain holders of warrants issued by the Company, as of the record date of August 10, 2017, to subscribe for up to an aggregate of 34,000,000 shares of common stock. Each subscription right included a basic subscription right, which entitled its holder to purchase 1.1608 shares of common stock at a subscription price of $1.00, and an over-subscription right, which entitled its holder to purchase up to 1.1608 shares of common stock at a subscription price of $1.00, subject to the availability and pro rata allocation of shares among rights holders exercising their over-subscription rights. F2 · shares: The reporting person exercised in full his basic subscription rights, pursuant to which he acquired 15,162 shares of common stock. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 22:15 UTC |
Boren DanielDirector
|
OtherSubscription Rights (right to buy) · Derivative | 2,858 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001455244-17-000030 · edgar.xml · derivative · entry 2 Boren Daniel · CIK 0001640217 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,634 shares Expires 2017-08-31 Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 22:15 UTC |
Boren DanielDirector
|
OtherCommon Stock | 6,634 | $1.00 | $6,634.00 |
DisclosureSEC source: 0001455244-17-000030 · edgar.xml · nonDerivative · entry 1 Boren Daniel · CIK 0001640217 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,492 F1 · shares: On August 14, 2017, Ekso Bionics Holdings, Inc. (the "Company") issued a press release announcing the commencement of a pro rata offering (the "Rights Offering") of rights to holders of the Company's common stock and certain holders of warrants issued by the Company, as of the record date of August 10, 2017, to subscribe for up to an aggregate of 34,000,000 shares of common stock. Each subscription right included a basic subscription right, which entitled its holder to purchase 1.1608 shares of common stock at a subscription price of $1.00, and an over-subscription right, which entitled its holder to purchase up to 1.1608 shares of common stock at a subscription price of $1.00, subject to the availability and pro rata allocation of shares among rights holders exercising their over-subscription rights. F2 · shares: The reporting person exercised in full his basic subscription rights, pursuant to which he acquired 3,317 shares of common stock. The reporting person also exercised in full his over-subscription rights for an additional 3,317 shares of common stock. Read SEC document |
| August 23, 2017 Filed Aug 25, 2017 22:09 UTC |
Angold RussPresident, EksoWorks
|
SaleCommon Stock | 9,352 | $1.33 | $12,438.16 |
DisclosureSEC source: 0001455244-17-000021 · edgar.xml · nonDerivative · entry 1 Angold Russ · CIK 0001640210 · President, EksoWorks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,326 Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:00 UTC |
Angold RussPresident, EksoWorks
|
SaleCommon Stock | 28,254 | $1.53 | $43,228.62 |
DisclosureSEC source: 0001455244-17-000019 · edgar.xml · nonDerivative · entry 1 Angold Russ · CIK 0001640210 · President, EksoWorks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,678 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.50 to $1.57, inclusive. The reporting person undertakes to provide to Ekso Bionics Holdings, Inc., any security holder of Ekso Bionics Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| August 15, 2017 Filed Aug 15, 2017 22:37 UTC |
Angold RussPresident, Ekso Labs
|
SaleCommon Stock | 50,000 | $1.59 | $79,500.00 |
DisclosureSEC source: 0001455244-17-000017 · edgar.xml · nonDerivative · entry 3 Angold Russ · CIK 0001640210 · President, Ekso Labs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,932 F3 · price: These shares were sold in multiple transactions at prices ranging from $1.55 to $1.68, inclusive. Read SEC document |
| August 14, 2017 Filed Aug 15, 2017 22:37 UTC |
Angold RussPresident, Ekso Labs
|
SaleCommon Stock | 71,746 | $1.59 | $114,076.14 |
DisclosureSEC source: 0001455244-17-000017 · edgar.xml · nonDerivative · entry 2 Angold Russ · CIK 0001640210 · President, Ekso Labs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,932 F2 · price: These shares were sold in multiple transactions at prices ranging from $1.55 to $1.74, inclusive. Read SEC document |
| August 11, 2017 Filed Aug 15, 2017 22:37 UTC |
Angold RussPresident, Ekso Labs
|
SaleCommon Stock | 100,000 | $1.50 | $150,000.00 |
DisclosureSEC source: 0001455244-17-000017 · edgar.xml · nonDerivative · entry 1 Angold Russ · CIK 0001640210 · President, Ekso Labs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,678 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.45 to $1.63, inclusive. The reporting person undertakes to provide to Ekso Bionics Holdings, Inc., any security holder of Ekso Bionics Holdings, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 16:14 UTC |
PALEFSKY HOWARD DDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001455244-17-000010 · edgar.xml · derivative · entry 1 PALEFSKY HOWARD D · CIK 0001094330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-07-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal monthly installments beginning on the one-month anniversary of the date of grant. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:15 UTC |
Wendell Amy McBrideDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001455244-17-000014 · edgar.xml · derivative · entry 1 Wendell Amy McBride · CIK 0001400568 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-07-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal monthly installments beginning on the one-month anniversary of the date of grant. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 16:13 UTC |
Stern StanleyDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001455244-17-000008 · edgar.xml · derivative · entry 1 Stern Stanley · CIK 0001316499 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-07-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal monthly installments beginning on the one-month anniversary of the date of grant. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 16:13 UTC |
SHERMAN STEVENDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001455244-17-000009 · edgar.xml · derivative · entry 1 SHERMAN STEVEN · CIK 0001201619 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-07-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal monthly installments beginning on the one-month anniversary of the date of grant. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:15 UTC |
Hamilton MarilynDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001455244-17-000013 · edgar.xml · derivative · entry 1 Hamilton Marilyn · CIK 0001640203 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-07-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal monthly installments beginning on the one-month anniversary of the date of grant. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:14 UTC |
Peurach JackDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001455244-17-000012 · edgar.xml · derivative · entry 1 Peurach Jack · CIK 0001640206 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-07-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal monthly installments beginning on the one-month anniversary of the date of grant. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:14 UTC |
Boren DanielDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001455244-17-000011 · edgar.xml · derivative · entry 1 Boren Daniel · CIK 0001640217 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-07-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal monthly installments beginning on the one-month anniversary of the date of grant. Read SEC document |
| April 20, 2017 Filed Apr 24, 2017 19:29 UTC |
Davault GregoryVice Pres., Global Marketing
|
GrantRestricted Stock Units · Derivative | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001578259-17-000018 · edgar.xml · derivative · entry 2 Davault Gregory · CIK 0001694979 · Vice Pres., Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Ekso Bionics Holdings, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on the one year anniversary of the date of grant. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on the one year anniversary of the date of grant. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| April 20, 2017 Filed Apr 24, 2017 19:29 UTC |
Davault GregoryVice Pres., Global Marketing
|
GrantEmployee Stock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001578259-17-000018 · edgar.xml · derivative · entry 1 Davault Gregory · CIK 0001694979 · Vice Pres., Global Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-04-20 F1 · derivative.exercise_date: The option becomes exercisable as to 25% of the total number of shares on the one year anniversary of the date of grant and thereafter vests in equal monthly installments for 36 months. Read SEC document |
| April 20, 2017 Filed Apr 24, 2017 19:25 UTC |
DeLonzor RussVice Pres., Operations
|
GrantRestricted Stock Units · Derivative | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001578259-17-000016 · edgar.xml · derivative · entry 2 DeLonzor Russ · CIK 0001694985 · Vice Pres., Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Ekso Bionics Holdings, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on the one year anniversary of the date of grant. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on the one year anniversary of the date of grant. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| April 20, 2017 Filed Apr 24, 2017 19:25 UTC |
DeLonzor RussVice Pres., Operations
|
GrantEmployee Stock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001578259-17-000016 · edgar.xml · derivative · entry 1 DeLonzor Russ · CIK 0001694985 · Vice Pres., Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-04-20 F1 · derivative.exercise_date: The option becomes exercisable as to 25% of the total number of shares on the one year anniversary of the date of grant and thereafter vests in equal monthly installments for 36 months. Read SEC document |
| April 20, 2017 Filed Apr 24, 2017 19:19 UTC |
SCHEDER-BIESCHIN MAXChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 37,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001578259-17-000012 · edgar.xml · derivative · entry 2 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Ekso Bionics Holdings, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on the one year anniversary of the date of grant. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on the one year anniversary of the date of grant. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| April 20, 2017 Filed Apr 24, 2017 19:19 UTC |
SCHEDER-BIESCHIN MAXChief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001578259-17-000012 · edgar.xml · derivative · entry 1 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-04-20 F1 · derivative.exercise_date: The option becomes exercisable as to 25% of the total number of shares on the one year anniversary of the date of grant and thereafter vests in equal monthly installments for 36 months. Read SEC document |
| April 20, 2017 Filed Apr 24, 2017 23:23 UTC |
Angold RussPresident, Ekso Labs
|
GrantRestricted Stock Units · Derivative | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001578259-17-000014 · edgar.xml · derivative · entry 2 Angold Russ · CIK 0001640210 · President, Ekso Labs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Ekso Bionics Holdings, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on the one year anniversary of the date of grant. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on the one year anniversary of the date of grant. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| April 20, 2017 Filed Apr 24, 2017 23:23 UTC |
Angold RussPresident, Ekso Labs
|
GrantEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001578259-17-000014 · edgar.xml · derivative · entry 1 Angold Russ · CIK 0001640210 · President, Ekso Labs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-04-20 F1 · derivative.exercise_date: The option becomes exercisable as to 25% of the total number of shares on the one year anniversary of the date of grant and thereafter vests in equal monthly installments for 36 months. Read SEC document |
| April 20, 2017 Filed Apr 24, 2017 23:16 UTC |
Looby ThomasDirector · President & CEO
|
GrantRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001578259-17-000010 · edgar.xml · derivative · entry 2 Looby Thomas · CIK 0001640215 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Ekso Bionics Holdings, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on the one year anniversary of the date of grant. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on the one year anniversary of the date of grant. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| April 20, 2017 Filed Apr 24, 2017 23:16 UTC |
Looby ThomasDirector · President & CEO
|
GrantEmployee Stock Option (right to buy) · Derivative | 107,500 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001578259-17-000010 · edgar.xml · derivative · entry 1 Looby Thomas · CIK 0001640215 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,500 Underlying: Common Stock · 107,500 shares Expires 2027-04-20 F1 · derivative.exercise_date: The option becomes exercisable as to 25% of the total number of shares on the one year anniversary of the date of grant and thereafter vests in equal monthly installments for 36 months. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 14:36 UTC |
SCHEDER-BIESCHIN MAXChief Financial Officer
|
PurchaseCommon Stock | 1,000 | $4.00 | $3,995.00 |
DisclosureSEC source: 0001342549-16-000004 · primary_doc.xml · nonDerivative · entry 1 SCHEDER-BIESCHIN MAX · CIK 0001342549 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,817 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.986 to $3.996. The Reporting Person undertakes to provide Ekso Bionics Holdings, Inc., any security holder of Ekso Bionics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 19:06 UTC |
Looby ThomasDirector · President & CEO
|
PurchaseCommon Stock | 1,000 | $3.98 | $3,983.00 |
DisclosureSEC source: 0001640215-16-000002 · primary_doc.xml · nonDerivative · entry 1 Looby Tom · CIK 0001640215 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.